Combining photodynamic therapy and ATM inhibition using modified bovine serum albumin: A co-delivery nano platform for eliciting pyroptosis and apoptosis to fuel TNBC therapy
Yuao Feng,
No information about this author
Zeliang Wu,
No information about this author
Hui Liu
No information about this author
et al.
International Journal of Biological Macromolecules,
Journal Year:
2025,
Volume and Issue:
unknown, P. 142140 - 142140
Published: March 1, 2025
Language: Английский
Dying to survive: harnessing inflammatory cell death for better immunotherapy
Trends in cancer,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 1, 2025
Language: Английский
Dysregulated Signaling Pathways in Canine Mammary Tumor and Human Triple Negative Breast Cancer: Advances and Potential Therapeutic Targets
Chen Mei,
No information about this author
Ying Liu,
No information about this author
Zhenyi Liu
No information about this author
et al.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
26(1), P. 145 - 145
Published: Dec. 27, 2024
In
2022,
human
breast
cancer
(HBC)
and
canine
mammary
tumors
(CMTs)
remained
the
most
prevalent
malignant
worldwide,
with
high
recurrence
lethality
rates,
posing
a
significant
threat
to
dog
health.
The
development
of
involves
multiple
signaling
pathways,
highlighting
need
for
effective
inhibitory
drugs
that
target
key
proteins
in
these
pathways.
This
article
reviews
dysregulation
EGFR,
PI3K/AKT/mTOR,
Hippo,
pyroptosis,
PD-1/PD-L1
pathways
HBC
CMT,
as
well
corresponding
used
inhibit
tumor
growth,
aim
providing
theoretical
support
more
efficient
drugs.
Language: Английский